Hunan Yimai, a subsidiary of Yimai Sunshine (02522), will acquire 100.0% of Zhonya Diagnosis's shares

Zhitong Finance App News, Yimai Yangguang (02522) announced that on June 9, 2025, the Company's subsidiaries, Hunan Yimai Sunshine Medical Imaging Diagnostic Center Co., Ltd. (Hunan Yimai) (as the buyer), and Changsha Zhongya Health Industry Group Co., Ltd. (as seller) and Changsha Zhongya Medical Imaging Diagnosis Co., Ltd. (Zhongya Diagnosis) will acquire 100.0% of Zhongya Diagnostics's shares (acquisition) from the seller at a total cost of RMB 29.5 million.

As of the date of this announcement, Hunan Yimai did not hold any shares in Zhongya Diagnosis, and the seller owned 100.0% of the shares in Zhongya Diagnosis. After the acquisition is completed, Hunan Yimai will own 100.0% of Zoya Diagnosis's shares. Zhongya Diagnosis will become a subsidiary of the Company, and its financial results will be comprehensively incorporated into the Group's financial statements.

Zhongya Diagnosis is a third-party independent imaging center registered under Chinese law that has a license to practice as a medical institution. It is mainly engaged in medical imaging examination and diagnosis business. Zhongya Diagnosis has established long-term partnerships with the top three hospitals in the province on medical imaging programs, serving more than 40,000 patients a year. Its service scale has always ranked among the top third-party imaging centers in the province. Following the completion of the acquisition, the Group aims to integrate its standardized products into the existing cooperation framework between Zhongya Diagnostics and the top three hospitals in the province. In addition, the Group plans to provide a large model of the medical imaging data base it has incubated, carry out research cooperation with the top three hospitals in the province, and expand the scope of cooperation. The acquisition aims to use the Group's mature product system and Zoya Diagnostics's solid business foundation to create synergy effects, achieve the breakthrough performance of the two imaging centers in Hunan Yimai and Zhongya Diagnostics, and strengthen their market position in central China. Therefore, the Board of Directors believes that the acquisition is in the overall interests of the Company and shareholders.